永井宏樹

ナガイヒロキ | Nagai Hiroki

所属機関・部署：
職名：医長

研究分野 (1件)：腫瘍診断、治療学

競争的資金等の研究課題 (2件)：

2016 - 2018 DOTATOC陽性胸腺腫瘍におけるOctreotide LAR/PSL併用療法
2015 - 2018 iPS細胞を用いた肺の臓器再生と疾患病態解明のための革新的バイオリソースの開発

論文 (50件)：

金田俊彦, 吉田博徳, 金永学, 阪森優一, 永井宏樹, 小笹裕晃, 吉岡弘鎮, 仲川宏昭, 富井啓介, 岡田あすか, et al. 進行非小細胞肺癌におけるCBDCA+PEM+BEV療法後のBEV、PEM、PEM+BEV維持療法を比較したランダム化第II相試験. 肺癌. 2020. 60. 6. 581-581
Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, et al. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer research. 2020. 40. 5. 2981-2987
Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Oncology. 2020. 1-8
Hironori Yoshida, Hiroki Nagai, Yuichi Sakamori, Hiroaki Ozasa, Takashi Nishimura, Keisuke Tomii, Toyohiro Hirai, Yukinori Matsuo, Yusuke Iizuka, Takashi Mizowaki, et al. Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer. IN VIVO. 2020. 34. 2. 897-902
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific reports. 2019. 9. 1. 17085-17085

MISC (57件)：

Hiroki Nagai, Ganepola A. Ganepola, Jin Lee, Eli Kirshner, Kevin Wood, Thomas Rakowski, Jason Suh, Eleonora Teplinsky, Alysha Insinga, John R. Rutledge, et al. Profiling novel subtypes of dendritic cells and T cells as biomarkers for the efficacy of immune checkpoint inhibitor monotherapy. AACR Annual Meeting 2020. 2020.6.22. Philadelphia, USA. 2020
Hiroki Nagai, Ganepola A.P. Ganepola, Jin Lee, Eli Kirshner, Kevin C. Wood, Thomas J. Rakowski, Jason Suh, Eleonora Teplinsky, Alysha Insinga, John R Rutledge, et al. Novel biomarker panel based on cellular and soluble checkpoint proteins for PD-1/PD-L1 blockade treatment efficacy. Journal of Clinical Oncology. 2020. 38. 15_suppl. 3045-3045
Yamamoto T, Ozasa H, Nomizo T, Ajimizu H, Yasuda Y, Tsuji T, Yoshida H, Nagai H, Sakamori Y, Hirai T, et al. Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab. ESMO 2018 Congress. 2018. 2018.10.20. Munich, Germany
Hiroki Nagai, Manabu Muto. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. International Journal of Clinical Oncology. 2018. 23. 3. 410-420
Funazo T, Ozasa H, Nomizo T, Tsuji T, Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T, Kim YH. Clinical impact of hypothyroidism and PD-L1 SNPs in patients having non-small cell lung cancer treated with nivolumab. AACR Annual Meeting 2018. 2018. 2018.4.18. Chicago, USA

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

永井 宏樹

永井宏樹